证券日报网讯 2月26日，常山药业在互动平台回答投资者提问时表示，二级市场股价波动受多种因素影 响，公司将持续努力提升经营质量，持续推进创新药审评工作，提升公司的内在价值。 （文章来源：证券日报） ...

Core Viewpoint - The company is actively progressing with the registration review of its innovative drug, CXHS2400019, and is prepared for potential commercialization while addressing industry competition and operational pressures [1]. Group 1: Drug Approval and Commercialization - The registration review for the innovative drug, CXHS2400019, is currently in progress, with the specific timeline dependent on the National Medical Products Administration (NMPA) [1]. - The company maintains good communication with clinical institutions involved in the research, which lays a solid foundation for future commercialization efforts [1]. - The company is open to collaborating with experienced and capable teams for the promotion of the drug [1]. Group 2: Business Strategy and Financial Performance - The company is actively expanding its overseas sales and enhancing its Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) operations to reduce costs and improve efficiency [1]. - The company reported its first loss in 2025, indicating a challenging competitive environment in the pharmaceutical sector [1]. - The management is focused on maintaining shareholder interests and ensuring sustainable operations, with plans to dynamically adjust development strategies based on industry trends and actual business conditions [1].